The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Cell Cycle

Volumn 9, Issue 9, 2010, Pages 1781-1791

  Abrams, Stephen L ^a   Steelman, Linda S ^a   Shelton, John G ^a   Wong, Ellis W T ^a   Chappell, William H ^a   Bäsecke, Jörg ^b   Stivala, Franca ^c   Donia, Marco ^c   Nicoletti, Ferdinando ^c   Libra, Massimo ^c   Martelli, Alberto M ^d,e   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CNR   (Italy)

Author keywords

Akt; Chemotherapeutic drugs; Drug resistance; Raf; Signal transduction inhibitors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE EXPRESSION; IC 50;

EID: 77953577584     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.9.11483     Document Type: Article

References (56)

1. Carracedo A, Baselaga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008; 7:3805-9.
2. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009; 8:403-13.
3. Foster DA, Toschi A. Targeting mTOR with rapamycin: one does not fit all. Cell Cycle 2009; 8:1026-9.
4. Lee JT, Lehmann BD, Terrrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7:1745-62.
5. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J, et al. Contributions of the Raf/ MEK/ERK, PI3K/PTEN/Akt/mTOR and JAK/STAT pathways to leukemia. Leukemia 2008; 22:686-707.
6. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, et al. Targeting Survival cascades induced by activation of Raf/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22:708-22.
7. Misaghian N, Ligresti G, Steelman LS, Bertand FE, Basecke J, Libra M, et al. Targeting the leukemic stem cell - the holy grail of leukemia therapy. Leukemia 2009; 23:25-42.
8. Hambardumyan D, Becher OJ, Holland EC. Cancer stem cells and survival pathways. Cell Cycle 2008; 7:1371-8.
9. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007; 6:1684-90.
10. Stuart SA, Minami Y, Wang JYJ. The CML stem cell: evolution of the progenitor. Cell Cycle 2009; 8:1338-43.
11. Li L, Borodyansky L, Yang Y. Genomic instability en route to and from cancer stem cells. Cell Cycle 2009; 8:1000-2.
12. Blagosklonny MV. Aging, stem cells and mammalian target of rapamycin: a prospect of pharmalogical rejuvenation of aging stem cells. Rejuvenation Res 2008; 11:801-8.
13. Blagosklonny MV. Aging: ROS or TOR. Cell Cycle 2008; 7:3344-54.
14. Blagosklonny MV, Campisi J. Cancer and aging: more puzzles, more promises. Cell Cycle 2008; 7:2615-8.
15. Blagosklonny MV. Program-like aging and mitochondria: instead of random damage by free radicals. J Cell Biochem 2007; 102:1389-99.
16. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7:3355-61.
17. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896-900.
18. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle 2009; 8:1901-4.
19. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-95.
20. Blagosklonny MV. Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009; 8:1883-7.
21. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009; 8:1352-8.
22. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong ET, Basecke J, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008; 22:2080-90.
23. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773:1263-84.
24. McCubrey JA, Chappell WH, Abrams SL, LaHair M, Franklin RA, Steelman LS. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Reg 2010; 50:In Press.
25. McKearn JP, McCubrey JA, Fagg B. Enrichment of hematopoietic precursor cells and cloning of multipotential B lymphocyte precursors. Proc Natl Acad Sci USA 1985; 85:7414-8.
26. McCubrey JA, Holland G, McKearn J, Risser R. Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms. Oncogene Res 1989; 4:97-109.
27. Mayo MW, Wang X-Y, Algate PA, Arana GF, Hoyle PE, Steelman LS, et al. Synergy between AUUUA motif disruption and enhancer insertion results in autocrine transformation of interleukin-3-dependent hematopoietic cells. Blood 1995; 78:3139-50.
28. Wang X-Y, McCubrey JA. Malignant transformation induced by cytokine genes: A comparison of the abilities of germline and mutated interleukin-3 genes to transform hematopoietic cells by transcriptional and post-transcriptional mechanisms. Cell Growth Differentiation 1996; 7:487-500.
29. Wang XY, McCubrey JA. Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation. Leukemia 1997; 11:1711-25.
30. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003; 22:2478-92.
31. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21:427-38.
32. Follo MY, Finelli C, Bosi C, Martinelli G, Mongiorgi S, Baccarani M, et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008; 22:198-200.
33. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, et al. The novel Akt inhibitor perifosine induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22:1106-16.
34. Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 2001; 20:4353-64.
35. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/ Akt/mTOR pathway inhibitors in suppressing IGFIR-mediated growth in hematopoietic cells. Leukemia 2006; 20:1254-60.
36. Steelman LS, Navolanic PN, Sokolosky M, Taylor JR, Lehmann BD, Chappell WH, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity of mTOR inhibitors. Oncogene 27:4086-95.
37. Lagadinou ED, Ziros PG, Tsopra OA, Dimas K, Kokkinou D, Thanopoulou E, et al. c-Jun N-terminal kinase activation failure is a new mechanism of antracycline resistance in acute myeloid leukemia. Leukemia 2008; 22:1899-908.
38. Gomes AR, Brosens JJ, Lam EWF. Resist of die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008; 7:3133-6.
39. 2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage. Cell Cycle 2008; 7:2877-85.
40. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT in NOTCH1-induced leukemia. Cell Cycle 2008; 7:965-70.
41. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, et al. Proapoptotitc activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22:147-60.
42. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20:911-28.
43. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007; 21:886-96.
44. Fernandez-Vidal A, Mazars A, Gautier ER, Prevost G, Payrastre B, Manenti S. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Cell Cycle 2009; 8:1373-9.
45. Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A, et al. Dual inhibition of class IA phosphatidylionsitol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Research 2009; 69:3520-8.
46. Sklandanosdki A, Bozko P, Sabisz M, Larsen AK. Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle 2007; 6:2268-75.
47. Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sashida G, et al. The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle 2009; 8:3120-4.
48. Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 2009; 8:2810-8.
49. Vaseva AV, Marchenko ND, Moll M. The transcription-independent mitochondrial p53 protein is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 2009; 8:1711-9.
50. Sohr S, Engleland K. RHAMM is differentially expressed in the cell cycle and downregulated by tumor suppressor p53. Cell Cycle 2008; 7:3448-60.
51. Paris R, Henry RE, Stephens SJ, McBryde M, Espinosa JM. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 2008; 7:2427-33.
52. Wade M, Rodewald LW, Espinosa JM, Wahl GM. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle 2008; 7:1973-82.
53. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7:1604-12.
54. Bykov VJ, Lambert JM, Hainaut P, Wiman KG. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 2009; 8:2509-17.
55. Varmark H, Sparks CA, Nordberg JJ, Koppetsch BS, Theurkauf WE. DNA damage-induced cell death is enhanced by progression through mitosis. Cell Cycle 2009; 8:2951-63.
56. Zhuang Z, Lu J, Lonser R, Kovach JS. Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phosphoproteome. Cell Cycle 2009; 8:3303-6.